https://doi.org/10.4081/btvb.2024.146
The intriguing association between cancer and congenital bleeding disorders
Submitted: 9 July 2024
Accepted: 4 November 2024
Published: 16 December 2024
Accepted: 4 November 2024
Abstract Views: 14
PDF: 4
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The relationship between congenital bleeding disorders and cancer is complex and multifactorial....
1. Liu CJ, Yu YB, Teng CJ, et al. Increased cancer risk in patients with haemophilia A: a nationwide population-based 14-year study in Taiwan. Haemophilia 2014;20:741–6.
DOI: https://doi.org/10.1111/hae.12450
2. Colonne CK, Favaloro EJ, Pasalic L. The intriguing connections between von Willebrand factor, ADAMTS13 and cancer. Healthcare (Basel) 2022;10:557.
DOI: https://doi.org/10.3390/healthcare10030557
3. Franchini M, Di Perna C, Santoro C, et al. Cancers in patients with von Willebrand disease: a survey from the Italian Association of Haemophilia Centres. Semin Thromb Hemost 2016;42:36–41.
DOI: https://doi.org/10.1055/s-0035-1564844
4. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110:815–25.
DOI: https://doi.org/10.1182/blood-2006-10-050435
5. Tagliaferri A, Di Perna C, Santoro C, et al. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost 2012;10:90–5.
DOI: https://doi.org/10.1111/j.1538-7836.2011.04566.x
6. Shetty S, Sharma N, Ghosh K. Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. Crit Rev Oncol Hematol 2016;99:129–33.
DOI: https://doi.org/10.1016/j.critrevonc.2015.12.009
7. Zanon E, Porreca A, Simioni P. Haemophilia and cancer: a literature review. J Clin Med 2024;19;13:1770.
DOI: https://doi.org/10.3390/jcm13061770
8. Lee CA. The natural history of HIV disease in haemophilia. Blood Rev 1998;12:135–44.
DOI: https://doi.org/10.1016/S0268-960X(98)90011-X
9. Franchini M, Tagliaferri A, Rossetti G, et al. The Natural History of Hepatitis C Virus Infection in Hemophiliacs. Hematology 2001;6:135–42.
DOI: https://doi.org/10.1080/10245332.2001.11746564
10. Franchini M. Haemophilia and cancer: a personal perspective. Blood Transfus 2013;11:26-31.
11. Ragni MV, Belle SH, Jaffe RA, et al. Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphomas and other malignancies in patients with hemophilia. Blood 1993;81:1889–97.
DOI: https://doi.org/10.1182/blood.V81.7.1889.1889
12. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425–31.
DOI: https://doi.org/10.1016/S0140-6736(97)05413-5
13. Miesbach W, Seifried E. Does haemophilia influence cancer‐related mortality in HIV‐negative patients? Haemophilia 2010;17:55–60.
DOI: https://doi.org/10.1111/j.1365-2516.2010.02364.x
14. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675–80.
DOI: https://doi.org/10.1056/NEJM199109053251002
15. Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014;109:542–53.
DOI: https://doi.org/10.1038/ajg.2014.11
16. Huang YC, Tsan YT, Chan WC, et al. Incidence and survival of cancers among 1,054 hemophilia patients: a nationwide and 14-year cohort study. Am J Hematol 2015;90.
DOI: https://doi.org/10.1002/ajh.23947
17. Hassan S, Monahan RC, Mauser-Bunschoten EP, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018. J Thromb Haemost 2021;19:645–53.
DOI: https://doi.org/10.1111/jth.15182
18. Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study. J Thromb Haemost 2006;4:510–6.
DOI: https://doi.org/10.1111/j.1538-7836.2006.01808.x
19. Franchini M, Lippi G, Montagnana M, et al. Hemophilia and cancer: A new challenge for hemophilia centers. Cancer Treat Rev 2009;35:374–7.
DOI: https://doi.org/10.1016/j.ctrv.2009.01.001
20. Tagalakis V, Tamim H, Blostein M, et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 2007;8:395–402.
DOI: https://doi.org/10.1016/S1470-2045(07)70046-3
21. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944–8.
DOI: https://doi.org/10.1200/JCO.2004.10.002
22. Brüggemann LW, Versteeg HH, Niers TM, et al. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Me 2008;12:2622–7.
DOI: https://doi.org/10.1111/j.1582-4934.2008.00316.x
23. Langer F, Amirkhosravi A, Ingersoll SB, et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006;4:1056–62.
DOI: https://doi.org/10.1111/j.1538-7836.2006.01883.x
24. Dolan G. The challenge of an ageing haemophilic population. Haemophilia 2010;16:11–6.
DOI: https://doi.org/10.1111/j.1365-2516.2010.02287.x
How to Cite
Zanon, E. (2024). The intriguing association between cancer and congenital bleeding disorders. Bleeding, Thrombosis and Vascular Biology, 3(3). https://doi.org/10.4081/btvb.2024.146
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Samantha Pasca, Cristina Santoro, Chiara Ambaglio, Marisanta Napolitano, Marta Milan, Letizia Natali, Silvia Nannizzi, Filippo Mori, Paolo Simioni, Ezio Zanon, Comparison among three different bleeding scores and the thrombin generation assay to assess the different hemorrhagic phenotypes in patients with FVII deficiency , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Roberto Mario Santi, Annamaria Fulghesu, Ezio Zanon, Erica De Candia, Elvira Grandone, Giancarlo Di Renzo, Claudia Succu, Valentina Tosto, Vincenzina Bruni, Paolo Gresele, Diagnosis and management of abnormal uterine bleeding in adolescence , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 1 (2024)
Similar Articles
- Marwa Eltemamy, Robert Namushi, Narayanamoorthi Saravanan, Importance of assessment of carotid plaques in the managementof acute ischemic stroke: floating intracarotid plaque , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Mosaad Almegren, Clinical and radiological characteristics of cerebral vein thrombosis: a retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Marialaura Bonaccio, Licia Iacoviello, Maria Benedetta Donati, It’s definitely time to consider diet in its ultra-processing form as a major risk factor for thrombotic vascular disorders , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Paolo Prandoni, Personalized bleeding risk assessment for atrial fibrillation patients on direct oral anticoagulants: the DOAC score , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Giovanni de Gaetano, Welcome to AICE and sincere wishes for peace for the new year 2024 , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Gianfranco De Girolamo, Luca Sarti, Sonia Cecoli, Karin Bonora, Chiara Ajolfi, Francesco Bellelli, Valeria Coluccio, Gualtiero Palareti, Marco Marietta, Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Rosina Albisinni, Tommaso Marrazzo, Arta Karruli, Sabrina Manduca, Giuseppe Nobile, Nicola Galdieri, Marisa De Feo, Successful treatment of aortic arch mural thrombosis with low-dose, ultra-slow-flow thrombolysis: a case report and literature review , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Setor K. Kunutsor, Sudhir Kurl, Ari Voutilainen, Jari Laukkanen, Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Kristen M. Sanfilippo, Tzu-Fei Wang, Venous thromboembolism and mortality in patients with hematological malignancies , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Marco P. Donadini, Walter Ageno, Milvexian and other drugs targeting Factor XI: a new era of anticoagulation? , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
You may also start an advanced similarity search for this article.
